CN101600417A - 用于神经递质的经鼻施用的控制释放递送系统 - Google Patents
用于神经递质的经鼻施用的控制释放递送系统 Download PDFInfo
- Publication number
- CN101600417A CN101600417A CNA2007800448143A CN200780044814A CN101600417A CN 101600417 A CN101600417 A CN 101600417A CN A2007800448143 A CNA2007800448143 A CN A2007800448143A CN 200780044814 A CN200780044814 A CN 200780044814A CN 101600417 A CN101600417 A CN 101600417A
- Authority
- CN
- China
- Prior art keywords
- preparation
- weight
- fatty acid
- acid ester
- neurotransmitter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002858 neurotransmitter agent Substances 0.000 title claims abstract description 30
- 238000013268 sustained release Methods 0.000 title description 3
- 239000012730 sustained-release form Substances 0.000 title description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 84
- 238000002360 preparation method Methods 0.000 claims abstract description 61
- 229960003638 dopamine Drugs 0.000 claims abstract description 42
- -1 fatty acid ester Chemical class 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 25
- 239000000194 fatty acid Substances 0.000 claims description 25
- 229930195729 fatty acid Natural products 0.000 claims description 25
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 239000004094 surface-active agent Substances 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 14
- 239000000969 carrier Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 7
- 239000003349 gelling agent Substances 0.000 claims description 6
- 125000005456 glyceride group Chemical group 0.000 claims description 6
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 24
- 210000002966 serum Anatomy 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 18
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 210000001331 nose Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000576 arachnoid Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical group CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及用于将神经递质例如多巴胺经鼻给药的盖仑凝胶制剂。本发明的具体的亲脂性或部分亲脂性的系统产生活性成分在血浆和脑中的高的生物利用度,所述高的生物利用度是由持续的血清水平和/或从鼻子到脑的直接转运或部分直接转运引起的。
Description
发明领域
[0001]本发明一般地涉及用于在经鼻施用之后对系统循环和/或脑控制释放神经递质的制剂。更具体地,本发明涉及通过经鼻给药对脑递送多巴胺。
发明背景
[0002]越来越多的证据认为作用于脑的化合物在控制受脑中受体影响的病症(例如,抑郁症、帕金森氏病、阿尔茨海默氏病、甚至是丧失性欲)的调节作用,所述作用于脑的化合物例如神经类固醇(例如,雄激素、孕激素)或神经递质(例如,多巴胺、3,4-二羟基苯基丙氨酸(左旋多巴,L-DOPA))。
[0003]神经类固醇作为几种神经递质的调节剂,作为兴奋剂或抑制剂起作用。神经递质是接转、放大和调节神经元和另一个细胞之间的电信号的化学品。一些神经递质是兴奋性的,其它的主要是抑制性的。在很多情形里,正如多巴胺的情况一样,它是决定递质为兴奋性的还是抑制性的受体。
[0004]脑漂浮在大约150ml的脑脊液(CSF)中,所述脑脊液缓慢地向下循环通过四个脑室,向上通过蛛网膜下腔并且通过蛛网膜绒毛(arachnoid vili)排出到脑静脉中。因为脑没有淋巴系统,CSF起到部分替代作用。尽管脑和CSF通过一定程度可渗透的软脑膜分开,但是血-脑脊液屏障和血脑屏障(BBB)代表着针对不合需要的血液物质的真正的保护。
[0005]BBB为脑产生受到保护的化学环境,其中某些分子可以执行与那些分子在身体的其余部分所执行的功能无关的功能。这对于例如神经递质多巴胺是特别重要的,所述多巴胺在作为输注施用时适合用于心脏病发作或肾衰竭,但是不适合于帕金森氏病的治疗,这是因为在通过这种途径(或经口给药)时,其不能通过BBB。
[0006]为了开发用于中枢神经系统(CNS)的病症的有效药物,已经研究了经鼻递送。在经鼻施用之后,分子的摄取是通过血脑屏障、还是通过鼻腔与CSF之间的直接转运、还是通过所述两种途径仍是需要讨论的问题。在第一种情况中,分子在从鼻粘膜吸收之后必须从系统循环跨过BBB。因为还有分子从脑外流,分子可能在不同的时期出现在脑中和血液中,具有不同的动力学或以不同的方法代谢。
[0007]经鼻药物递送提供许多优点,包括有可能直接进入脑、由于鼻中存在大量的毛细血管引起的迅速吸附、作用的快速起效、避免了肝脏的首过代谢、对于慢性药物的适用性、和容易给药。还已知的是,与大的和/或离子化的分子相反,具有充分低的分子量的亲脂性药物化合物一般是容易被鼻粘膜所吸收的。
[0008]因为药物进入到脑中的扩散似乎是主要取决于它们的物理化学性质,对于目前研究的大多数药物来说,在脑组织中检测到的总量通常只有经鼻给药剂量的2-3%。因此,关于制剂对这种摄取的影响的研究长久以来一直需要,以便确定可以增加脑利用度的制剂。
[0009]然而,长时间保持恒定的体内治疗药物浓度,特别是在脑中长时间保持恒定的体内治疗药物浓度是有问题的。治疗剂从沉积位置的快速经粘膜清除以及鼻腔中酶的存在(所述酶可以引起治疗剂的降解)产生短的用于吸收的时间跨度。另外,对调节为脑直接递送分子的机制以及必要条件的了解尚不充分。
[0010]在本领域中已经进行许多尝试,试图克服这些限制。GB1987000012176描述了使用生物粘性的微球体来增加在鼻腔中的停留时间。还发现使用增强剂改善鼻粘膜的渗透性,并且稳定剂阻止药物降解。PCT/GB98/01147(美国专利6,432,440)描述了使用原位凝胶化的果胶制剂。
[0011]Bayne的美国再公告专利RE29,892公开了通过给予包括多巴胺和一种肼化物的组合物来提高脑组织中的多巴胺浓度的方法。所公开的方法允许将组合物局部、经直肠、经口、或非肠道给药。优选的组合物包括肼化合物例如L-α-肼基-α-低级烷基-3,4-二羟基苯基丙酸和左旋多巴及其药学接受的盐。
[0012]Haffner等人的美国专利4,826,852公开了给予麦角碱基(ergolinyl)化合物来增加哺乳动物脑组织中的多巴胺浓度的方法。Haffner的特定目的是治疗精神病例如精神分裂症。
[0013]另外,Wenzel等人的美国专利5,624,960公开了通过口服给予包含左旋多巴和卡比多巴的组合物来治疗帕金森氏病。Mandel等人的美国专利6,319,905公开了通过基因治疗紧密地调节哺乳动物脑中的左旋多巴的产生。使用了调节剂例如四氢蝶呤(PH4)来控制多巴胺的生成。
[0014]需要鉴定增加脑对神经递质(特别是多巴胺)的利用度的制剂。神经递质可以调节或控制情绪的管理以及相关的精神性障碍(例如抑郁症)。鉴定可以增加多巴胺的生物利用度的制剂为治疗与脑中多巴胺不足有关的疾病提供了可能性,所述疾病尤其是例如抑郁症、帕金森氏病、注意力缺乏活动过强病症(ADHD)、或毒瘾或酒瘾。
发明内容
[0015]本发明人出人意料地发现,将各种神经递质药物结合在具体的亲脂性或部分亲脂性的系统中产生更高的生物利用度,其通常是由于血浆和CSF中的持续的血清水平引起的。
[0016]本发明包括用于经鼻施用的制剂,包括:(a)至少一种活性的神经递质药物;(b)至少一种亲脂性或部分亲脂性的载体;和(c)化合物或多种化合物的混合物,所述化合物或多种化合物的混合物具有降低表面张力的活性,其量对于在制剂接触水时就地生成乳液是有效的。
[0017]在本发明的一个方面中,活性成分是神经递质药物。优选地,所述神经递质是多巴胺。优选多巴胺以0.5-6重量%、优选2-4重量%、更优选0.5-2重量%、最优选大约2重量%的量被包括在制剂中。
[0018]优选地,亲脂性载体包括油。更优选地,所述油是植物油。最优选地,所述油是蓖麻油。
[0019]本发明的优选实施方案包括占制剂的30-98重量%、优选60-98重量%、更优选75-95重量%、更优选85%-95重量%、最优选大约90重量%的量的油。
[0020]另一个实施方案的特征在于组分(c)包括至少一种表面活性剂和/或至少一种湿润剂、或其混合物,所述表面活性剂选自卵磷脂、多元醇的脂肪酸酯、山梨聚糖的脂肪酸酯、聚氧乙烯山梨聚糖的脂肪酸酯、聚氧化乙烯的脂肪酸酯、蔗糖的脂肪酸酯、聚甘油的脂肪酸酯,所述湿润剂选自山梨醇、甘油、聚乙二醇、和聚乙二醇甘油脂肪酸酯。优选地,组分(c)包括油酰基聚乙二醇甘油酯或油酰基聚乙二醇甘油酯的混合物。
[0021]组分(c)以1-20重量%、优选1-10重量%、更优选1-5重量%、最优选大约4重量%的量被包括在制剂中。
[0022]另一个实施方案包括粘度调节剂。优选地,所述粘度调节剂包括选自以下的增稠剂或胶凝剂:纤维素和纤维素衍生物、聚糖、卡波姆、聚乙烯醇、聚维酮、胶体二氧化硅、鲸蜡醇、硬脂酸、蜂蜡、矿脂、甘油三酯和羊毛脂、或其混合物。更优选地,所述增粘剂是胶体二氧化硅。
[0023]所述粘度调节剂以0.5-10重量%、优选0.5-5重量%、更优选1-3重量%、最优选大约3重量%的量被包括在制剂中。
[0024]尽管不希望束缚于理论,但是认为本发明的盖仑制剂的经鼻给药能够恢复分子的选择性作用,这样又可以提供新的临床应用。认为这种作用是由于本发明的盖仑凝胶制剂使得有可能进入脑中。经鼻施用本发明的盖仑制剂产生出人意料的和与常规制剂相比不同的化合物对脑的作用。
附图简述
[0025]图1示出了经鼻给药的多巴胺凝胶剂对抑郁大鼠的不动性和攀爬的影响。
[0026]图2表示在将多巴胺经鼻给药之后在伏核和新纹状体中的多巴胺和代谢物的浓度。
发明详述
[0027]本发明的盖仑凝胶制剂是化学上和物理上稳定的,并且可以为药理学活性物质的悬浮液或溶液。优选地,将本发明的盖仑凝胶制剂填充到即使在较高的粘度下也能够精确递送上述制剂剂量的不含防腐剂的设备中。
[0028]在将本发明的盖仑凝胶制剂经鼻施用之后,活性成分或活性成分粒子有效地被截留在沉积位置并且以可预测的速率被吸收通过患者的粘膜,从而限制可能的由代谢酶和/或蛋白结合引起的减活。
[0029]还应该理解,本文中使用的术语和措辞具有与其各自相应的调查和研究领域相对应的这种术语和措辞的普通含义,除非本文中规定了其具有特定的含义。
[0030]术语“更高的利用度”应该是指在施用神经递质之后,在延长的时间段保持显著的和恒定的体内,特别是在脑中的治疗药物浓度。
A.神经递质
[0031]本发明的组合物包括神经递质。根据定义,神经递质引起快速的、短暂的和显著的应答。神经递质倾向于迅速降解,产生静息膜电位的复位。许多神经递质共有的结构部分为儿茶酚部分。
[0032]神经递质例如肾上腺素和多巴胺包含典型地从氨基酸酪氨酸(tryosine)合成的儿茶酚部分。
[0033]通常与许多反应有关的一种神经递质是多巴胺或4-(2-氨基乙基)-1,2-苯二酚。多巴胺通常被认为是具有α和β肾上腺能活性的内源性儿茶酚胺。
[0034]多巴胺或左旋多巴通常是从氨基酪胺合成的。其它神经递质通常由突触前神经元的末梢中的突触小泡限定并且包含药物,其在适当时间响应于充分量的刺激而释放,以便诱导突触后细胞的应答;将所述药物离子电渗到突触间隙中诱导相同的应答;并且该物质迅速地降解,使得电位复位。
[0035]已知具有各种用途的其它儿茶酚胺类包括肾上腺素、去甲肾上腺素、血清素。
[0036]神经递质药物以0.2-6重量%、优选0.2-4重量%、更优选0.2-2重量%、最优选大约2重量%的量被包括在制剂中。
B.亲脂性载体
[0037]本发明的载体用于使本发明的各种组分乳化或支持本发明的各种组分。为此,所述载体具有亲脂性的性质或特征。适合的油类家族包括脂肪酸和例如无机油和植物油的油类。特别地,衍生自植物的脂肪酸和油类特别有用。直链和支链的酸类和油类都是有用的,包括具有各种水平饱和度和取代作用的那些油类和酸类。尤其是包括甲酸、乙酸、丙酸、丁酸、戊酸、己酸、庚酸(emanthic acid)、辛酸、壬酸、癸酸、月桂酸、肉豆蔻酸、棕榈酸和硬脂酸的链长都是有用的油和酸部分的代表。
[0038]术语“亲脂性载体”应该包括但不限于植物油,例如蓖麻油、豆油、芝麻油、或花生油,脂肪酸酯例如油酸乙酯和油酸油酯、肉豆蔻酸异丙酯、中链甘油三酯、脂肪酸的甘油酯,或聚乙二醇,磷脂,白色软石蜡,或氢化蓖麻油,或其混合物。在一个方面中,还可以将活性成分结合在油混合物中,在一个优选的方面中,所述植物油是蓖麻油。
[0039]构成有效量的亲脂性载体的特定量取决于在制剂中使用的特定的粘度调节剂。因此,列举用于本发明的具体制剂中的具体量是不实际的。然而,亲脂性载体通常以占制剂的30-98重量%、优选60-98重量%、更优选75-95重量%、更优选85%-95重量%、最优选大约90重量%的量存在。
C.表面活性剂
[0040]本发明的表面活性剂或表面活化剂用于降低本发明的组合物中的表面张力。表面活化剂通常被认为是同时具有亲水性和疏水性特征的那些组合物。表面活性剂的亲脂性特征倾向于采取悬垂部分的形式,所述悬垂部分即使有也是仅有很少的电荷。相反,表面活性剂的亲水性特征倾向于是带电的,并且还指示该表面活性剂的所属类别。例如,可用于本发明的表面活性剂包括非离子型表面活性剂、离子型表面活性剂、两性表面活性剂、和阳离子型表面活性剂。
[0041]组分(c)为具有降低表面张力活性的化合物或化合物的混合物,包括至少一种表面活性剂和/或至少一种湿润剂,所述表面活性剂例如但不限于卵磷脂、多元醇的脂肪酸酯、山梨聚糖的脂肪酸酯、聚氧乙烯山梨聚糖的脂肪酸酯、聚氧乙烯的脂肪酸酯、蔗糖的脂肪酸酯、聚甘油的脂肪酸酯,所述湿润剂例如山梨醇、甘油、聚乙二醇、或聚乙二醇甘油脂肪酸酯。然而,特别有用的是油酰基聚乙二醇甘油酯(例如M 1944 CS,得自Gattefosse(Saint-Priest,France))。
[0042]在另一个方面中,可以将活性成分结合在表面活性剂混合物中。构成有效量的表面活性剂的特定量取决于在制剂中使用的特定的油或油混合物。因此,列举用于本发明的具体制剂中的具体量是不实际的。然而,表面活性剂通常以1-20重量%、优选1-10重量%、更优选1-5重量%、最优选大约4重量%的量存在于制剂中。
D.粘度调节剂
[0043]术语“粘度调节剂”是指增稠剂或胶凝剂。其实例包括但不限于纤维素及其衍生物、聚糖、卡波姆、聚乙烯醇、聚维酮、胶体二氧化硅、鲸蜡醇、硬脂酸、蜂蜡、矿脂、甘油三酯、羊毛脂等。优选的粘度调节剂是胶体二氧化硅(例如ACROSEL得自Degussa)。
[0044]还有可能将活性成分结合在增稠剂或胶凝剂的混合物中。构成有效量的增稠剂/胶凝剂的特定量取决于在制剂中使用的特定的油或油混合物。因此,列举用于本发明的具体制剂中的具体量是不实际的。然而,增稠剂/胶凝剂通常以0.5-10重量%、优选0.5-5重量%、更优选1-3重量%、最优选大约3重量%的量存在于制剂中。
表
重量%
可用的 | 优选的 | 更优选的 | |
神经递质 | 0.5-6 | 2-4 | 0.5-2 |
亲脂性载体 | 30-98 | 60-98 | 85-95 |
表面活性剂 | 1-20 | 1-10 | 1-5 |
粘度调节剂 | 0.5-10 | 0.5-5 | 1-3 |
制剂
[0045]通常,可以通过以下常规方法非常容易地制备本发明的盖仑制剂:
[0046]将亲脂性载体和乳化剂填充到搅拌器容器中并且混入大约75%的粘度调节剂。在搅拌下加入活性成分,得到活性成分的均质分散体。然后,用其余的粘度调节剂将制剂调节到必要的粘度。
[0047]优选将制剂填充到不含防腐剂的容器中。
[0048]因为神经递质可能在水中具有低的溶解度水平,其从制剂中的释放是吸附的限速步骤。已经出人意料地发现,将活性剂结合在本发明的包含适合的表面活性剂的含油制剂中产生生理学的血清水平并且产生随时间为稳态的、持续的激素作用。
[0049]由于神经递质药物在含油载体中的溶解度以及因为制剂的粘度使其长时间保持在粘膜上,神经递质药物的释放是持续的。
[0050]在制剂接触粘膜的湿度时,活性成分的沉淀被表面活性剂形成包含活性成分的油滴的能力所阻碍。因此,通过向制剂中加入适合的表面活性剂,活性成分的溶出模式变得更有利和更有效,因为在溶出方面没有大的变化性,这样确保了生物等效性。
[0051]还可以将本发明的活性成分以经过处理的形式,例如尤其是微球体、脂质体的形式引入到制剂中。
[0052]还可以将本发明的制剂加工为粉末形式,例如通过冷冻干燥或喷雾干燥。
表1.最优选的制剂
化合物 | 每个容器的量 | 每次喷雾的递送量 |
多巴胺 | 2% | ≈2.8mg |
胶体二氧化硅 | 3% | ≈4.2mg |
油酰基聚乙二醇-甘油酯 | 4% | ≈5.6mg |
蓖麻油 | 91% | ≈127.4mg |
具体实施方式
[0053]以下实施例意在进一步说明而不是用于限制本发明的实施方案。
实施例1:对大鼠经鼻给药多巴胺
[0054]将本发明制剂的多巴胺(DA)凝胶经鼻给药大鼠,将所述大鼠用于验证的“强迫游泳试验”。如图1所示,多巴胺的给药产生抗抑郁样作用。如图2所示,在通过本发明的制剂经鼻给药多巴胺之后,观察到在新纹状体和复侧纹状体(伏核)中的强烈的多巴胺能活性。
[0055]通常,在观察到抗抑郁作用之前,抗抑郁药必须服用较长的时间。出人意料的是,在对大鼠经鼻施用多巴胺凝胶制剂之后,在数小时内出现抗抑郁作用并且没有任何副作用,例如已知在使用地昔帕明(冷漠)或氟西汀(体重损失)时已知的那些副作用。
[0056]在将多巴胺在本发明的凝胶制剂中经鼻施用之后,出人意料地发现,伏核和新纹状体中的多巴胺浓度非常迅速地增加超过1000%。这些结果与以前描述的那些不同。在将多巴胺水溶液对小鼠经鼻施用之后,Bjorn Jansson,Comprehensive Summaries of UppsalaDissertations from the Faculty of Pharmacy 305(2004),在嗅球中发现多巴胺,但是在四小时之后达峰值。在对大鼠经鼻施用多巴胺水溶液之后,Maria Dahlin,Comprehensive Summaries of UppsalaDissertations from the Faculty of Pharmacy 240(2000),在短时间之后在脑脊液(CSF)中发现多巴胺,但是化合物浓度从基线的增加比本发明的经鼻凝胶低得多。Ikeda等人,Chem.Pharm.Bull.40(8):2155-2158(1992)分别使用赋形剂羟基丙基纤维素(HPC)和氮酮(1-十二烷基氮杂环庚-2-酮)使经鼻给予的多巴胺的生物利用度有一定程度的提高。De Souza Silva等人,Synapse 27:294-302(1997)表明,通过对大鼠经鼻施用左旋多巴甲酯水溶液(50mg/kg),新纹状体中的多巴胺水平可以增加约130%。代谢物3,4-二羟基苯基乙酸(DOPAC)和高香草酸(homovanillic acid,HVA)略有增加,与De Souza Silva等人,J.Neurochem.68(1):233-239(1997)中腹腔内给予左旋多巴甲酯的观察结果相反。
[0057]此外,多巴胺的代谢似乎是与以前的描述完全不同。非常出乎意料的是,如图2所示,脑脊液(CSF)中的多巴胺没有如通常所观察的那样被代谢为3,4-二羟基苯基乙酸(DOPAC)或高香草酸(HVA)。因此,这些结果证明,将多巴胺在本发明的凝胶制剂中经鼻施用可用于与脑中多巴胺不足有关的疾病的病因治疗,所述疾病例如帕金森氏病、注意力缺乏活动过强病症(ADHD)、或毒瘾和/或酒瘾。
[0058]在前述说明书、权利要求和/或附图中公开的特征可以分别地和以其任何组合作为用于实现本发明的多种形式的素材。
Claims (14)
1.用于经鼻施用的制剂,包括:(a)至少一种神经递质;(b)至少一种亲脂性或部分亲脂性的载体;和(c)化合物或多种化合物的混合物,所述化合物或多种化合物的混合物具有降低表面张力的活性,其量对于在制剂接触水时就地生成乳液是有效的。
2.权利要求1的制剂,其中所述亲脂性载体包括一种油。
3.权利要求2的制剂,其中所述油是植物油。
4.权利要求2和3的制剂,其中所述油是蓖麻油。
5.权利要求1的制剂,其中油的量占制剂的30-98重量%、优选60-98重量%、更优选75-95重量%、更优选85%-95重量%、最优选大约90重量%。
6.权利要求1的制剂,其中组分(c)包括至少一种表面活性剂和/或至少一种湿润剂、或其混合物,所述表面活性剂选自卵磷脂、多元醇的脂肪酸酯、山梨聚糖的脂肪酸酯、聚氧乙烯山梨聚糖的脂肪酸酯、聚氧化乙烯的脂肪酸酯、蔗糖的脂肪酸酯、聚甘油的脂肪酸酯,所述湿润剂选自山梨醇、甘油、聚乙二醇、和聚乙二醇甘油脂肪酸酯。
7.权利要求6的制剂,其中组分(c)包括油酰基聚乙二醇甘油酯或油酰基聚乙二醇甘油酯的混合物。
8.权利要求6的制剂,其中组分(c)以1-20重量%、优选1-10重量%、更优选1-5重量%、最优选大约4重量%的量被包括在制剂中。
9.权利要求1的制剂,其另外包括粘度调节剂。
10.权利要求9的制剂,其中所述粘度调节剂包括选自以下的增稠剂或胶凝剂:纤维素和纤维素衍生物、聚糖、卡波姆、聚乙烯醇、聚维酮、胶体二氧化硅、鲸蜡醇、硬脂酸、蜂蜡、矿脂、甘油三酯和羊毛脂、或其混合物。
11.权利要求10的制剂,其中所述粘度调节剂是胶体二氧化硅。
12.权利要求9的制剂,其中粘度调节剂以0.5-10重量%、优选0.5-5重量%、更优选1-3重量%、最优选大约3重量%的量被包括在制剂中。
13.权利要求1的制剂,其中所述神经递质是多巴胺。
14.权利要求1的制剂,其中所述神经递质以0.2-6重量%、优选0.2-4重量%、更优选0.2-2重量%、最优选大约2重量%的量被包括在制剂中。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82810906P | 2006-10-04 | 2006-10-04 | |
US60/828,109 | 2006-10-04 | ||
PCT/EP2007/008409 WO2008040488A1 (en) | 2006-10-04 | 2007-09-27 | Controlled release delivery system for nasal application of neurotransmitters |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101600417A true CN101600417A (zh) | 2009-12-09 |
CN101600417B CN101600417B (zh) | 2012-05-30 |
Family
ID=38799348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800448143A Expired - Fee Related CN101600417B (zh) | 2006-10-04 | 2007-09-27 | 用于神经递质的经鼻施用的控制释放递送系统 |
Country Status (20)
Country | Link |
---|---|
US (4) | US20090227550A1 (zh) |
EP (1) | EP2068825B1 (zh) |
JP (1) | JP5248510B2 (zh) |
KR (1) | KR101307133B1 (zh) |
CN (1) | CN101600417B (zh) |
AT (1) | ATE496617T1 (zh) |
AU (1) | AU2007304471B2 (zh) |
BR (1) | BRPI0717509B8 (zh) |
CA (1) | CA2664427C (zh) |
DE (1) | DE602007012276D1 (zh) |
DK (1) | DK2068825T3 (zh) |
ES (1) | ES2358619T3 (zh) |
HK (1) | HK1137658A1 (zh) |
MX (1) | MX2009003654A (zh) |
NO (1) | NO339802B1 (zh) |
PL (1) | PL2068825T3 (zh) |
PT (1) | PT2068825E (zh) |
RU (1) | RU2480208C2 (zh) |
WO (1) | WO2008040488A1 (zh) |
ZA (1) | ZA200902902B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110461340A (zh) * | 2017-01-20 | 2019-11-15 | 马特恩制药股份公司 | 用于降低暴露于空气污染物的风险的鼻用药物组合物 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
KR101307133B1 (ko) | 2006-10-04 | 2013-09-12 | 엠엔피 페이턴트 악티엔게젤샤프트 | 신경전달물질의 비강 투여를 위한 서방형 전달 시스템 |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
EA201391702A1 (ru) | 2011-05-13 | 2014-10-30 | Тримел Биофарма Срл | Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
CA3034552C (en) * | 2011-05-15 | 2023-02-07 | Acerus Biopharma Inc. | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
DE102012015248A1 (de) * | 2012-08-05 | 2014-02-06 | Naum Goldstein | Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2016013298A1 (ja) * | 2014-07-25 | 2016-01-28 | 日本電気株式会社 | 画像処理装置、監視システム、画像処理方法、及びプログラム |
MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
SG11201810628XA (en) * | 2016-06-03 | 2018-12-28 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
SG11202006374VA (en) | 2018-01-11 | 2020-07-29 | M et P Pharma AG | Treatment of demyelinating diseases |
WO2019148140A2 (en) * | 2018-01-26 | 2019-08-01 | Wu Joseph C | Implantable biomaterials that enhance stem cell survival and function |
WO2019199704A1 (en) | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
US20220062165A1 (en) * | 2018-04-17 | 2022-03-03 | M et P Pharma AG | Compositions and methods for intranasal delivery of pregnenolone |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE943792C (de) | 1949-02-18 | 1956-06-01 | Organon Nv | Verfahren zur Herstellung von injizierbaren Hormonpraeparaten |
GB1032874A (en) | 1964-02-13 | 1966-06-15 | Du Pont | Stabilized polyoxymethylenes |
US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
US4123417A (en) | 1974-10-10 | 1978-10-31 | Mobil Oil Corporation | Low density polyethylene toughened with ethylene/propylene copolymer |
NL7506407A (nl) | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
NL7510104A (nl) | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
US4315925A (en) | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
DE3151912A1 (de) | 1981-12-23 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel |
US4546882A (en) | 1983-02-07 | 1985-10-15 | American Can Company | Package having oil-containing product |
US4581255A (en) * | 1983-08-30 | 1986-04-08 | Abitibi-Price Corporation | Method of making simulated ceramic tile |
JPS60136283U (ja) | 1984-02-22 | 1985-09-10 | 株式会社シマノ | キヤリバ−ブレ−キ |
ZA852884B (en) * | 1984-04-25 | 1986-11-26 | Lilly Co Eli | Sustained release intranasal formulation and method of use thereof |
US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4752425A (en) | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US4786678A (en) | 1986-12-29 | 1988-11-22 | Mobil Oil Corporation | Method of producing films from polyethylene resin, an additive and a second polymeric resin |
US5049387A (en) | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
JPS646716A (en) | 1987-06-27 | 1989-01-11 | Suzuki Motor Co | Displacement measuring apparatus |
JP2543708B2 (ja) | 1987-07-13 | 1996-10-16 | 旭化成工業株式会社 | 難溶性薬物を封入したエマルジョン製剤の製造方法 |
JPH01160916A (ja) * | 1987-12-18 | 1989-06-23 | Tanabe Seiyaku Co Ltd | ドーパミン経鼻投与製剤 |
NL8801670A (nl) | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5624960A (en) * | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
US5500261A (en) | 1991-05-24 | 1996-03-19 | Kao Corporation | Resin composition and a container |
US5221698A (en) | 1991-06-27 | 1993-06-22 | The Regents Of The University Of Michigan | Bioactive composition |
DE4218291A1 (de) | 1992-06-03 | 1993-12-09 | Mattern Et Partner Pharmazeuti | Dosierspray für pernasale Applikation |
US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
SE9301171D0 (sv) | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
ATE201980T1 (de) | 1994-02-04 | 2001-06-15 | Scotia Lipidteknik Ab | Präparate mit lipophilen trägerstoffen |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
WO1996011022A1 (fr) | 1994-10-05 | 1996-04-18 | Hisamitsu Pharmaceutical Co., Inc. | Constituants de composition medicamenteuse comprenant des derives de o-toluidine n-substituee et preparation absorbable par voie cutanee |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US5897894A (en) | 1997-12-29 | 1999-04-27 | General Mills, Inc. | Microwave popcorn with coarse salt crystals and method of preparation |
AU3843999A (en) * | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
FR2779438B1 (fr) | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
US6838091B2 (en) * | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
GB9828861D0 (en) * | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2000059512A1 (en) | 1999-04-01 | 2000-10-12 | Akzo Nobel N.V. | Formulation comprising testosteron undecanoate and castor oil |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
TR200200406T2 (tr) | 1999-06-11 | 2002-06-21 | Watson Pharmaceuticals, Inc. | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması |
EP1214059B1 (en) | 1999-09-21 | 2005-05-25 | Skyepharma Canada Inc. | Surface modified particulate compositions of biologically active substances |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6231662B1 (en) | 1999-10-25 | 2001-05-15 | George K. Atkinson | Surface treatments for titanium dioxide and other industrial pigments |
WO2001041732A1 (en) | 1999-12-06 | 2001-06-14 | Gore Stanley L | Compositions and methods for intranasal delivery of active agents to the brain |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
US20020114933A1 (en) | 2000-12-28 | 2002-08-22 | Gould Richard J. | Grease masking packaging materials and methods thereof |
US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
KR20040052489A (ko) | 2001-03-06 | 2004-06-23 | 셀러지 파마세우티칼스, 인크 | 비뇨생식기 장애 치료용 화합물 및 그 방법 |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
US6800363B2 (en) | 2001-08-30 | 2004-10-05 | Toray Plastics, Inc. | Polyolefin oil resistant film using porous particles |
US6815506B2 (en) | 2001-10-15 | 2004-11-09 | Jsr Corporation | Oil-resistant thermoplastic elastomer composition and moldings using the same |
DE60320940D1 (de) | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US6958142B2 (en) | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
US7029657B2 (en) | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
WO2005065185A2 (en) | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
CA2670355A1 (en) * | 2005-11-21 | 2008-04-24 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
KR101307133B1 (ko) | 2006-10-04 | 2013-09-12 | 엠엔피 페이턴트 악티엔게젤샤프트 | 신경전달물질의 비강 투여를 위한 서방형 전달 시스템 |
-
2007
- 2007-09-27 KR KR1020097009279A patent/KR101307133B1/ko active IP Right Grant
- 2007-09-27 DK DK07818492.6T patent/DK2068825T3/da active
- 2007-09-27 MX MX2009003654A patent/MX2009003654A/es active IP Right Grant
- 2007-09-27 WO PCT/EP2007/008409 patent/WO2008040488A1/en active Application Filing
- 2007-09-27 PL PL07818492T patent/PL2068825T3/pl unknown
- 2007-09-27 AU AU2007304471A patent/AU2007304471B2/en not_active Ceased
- 2007-09-27 BR BRPI0717509A patent/BRPI0717509B8/pt not_active IP Right Cessation
- 2007-09-27 DE DE602007012276T patent/DE602007012276D1/de active Active
- 2007-09-27 AT AT07818492T patent/ATE496617T1/de active
- 2007-09-27 ES ES07818492T patent/ES2358619T3/es active Active
- 2007-09-27 CN CN2007800448143A patent/CN101600417B/zh not_active Expired - Fee Related
- 2007-09-27 JP JP2009530783A patent/JP5248510B2/ja not_active Expired - Fee Related
- 2007-09-27 RU RU2009116609/15A patent/RU2480208C2/ru active
- 2007-09-27 PT PT07818492T patent/PT2068825E/pt unknown
- 2007-09-27 CA CA2664427A patent/CA2664427C/en active Active
- 2007-09-27 ZA ZA200902902A patent/ZA200902902B/xx unknown
- 2007-09-27 EP EP07818492A patent/EP2068825B1/en active Active
-
2009
- 2009-04-06 US US12/418,917 patent/US20090227550A1/en not_active Abandoned
- 2009-04-28 NO NO20091695A patent/NO339802B1/no unknown
-
2010
- 2010-03-19 HK HK10102895.0A patent/HK1137658A1/xx not_active IP Right Cessation
-
2011
- 2011-07-30 US US13/194,926 patent/US9186320B2/en active Active
-
2015
- 2015-10-13 US US14/881,332 patent/US9801834B2/en active Active
-
2017
- 2017-09-26 US US15/716,337 patent/US20180200203A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110461340A (zh) * | 2017-01-20 | 2019-11-15 | 马特恩制药股份公司 | 用于降低暴露于空气污染物的风险的鼻用药物组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101600417B (zh) | 用于神经递质的经鼻施用的控制释放递送系统 | |
US11793786B2 (en) | Administration of benzodiazepine compositions | |
ES2258694T3 (es) | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. | |
Khosrow Tayebati et al. | Intranasal drug delivery to the central nervous system: present status and future outlook | |
JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法 | |
US10751353B2 (en) | Compositions and methods for treating an aggregation disease or disorder | |
CZ291284B6 (cs) | Vodné suspenze 9-hydroxyrisperidon esterů mastných kyselin | |
SK182899A3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ELETRIPTAN HEMISULPHATEì (54) AND CAFFEINE | |
US20090118331A1 (en) | Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse | |
CN114366714B (zh) | 一种阿戈美拉汀混悬鼻喷剂及其应用 | |
WO2018055641A1 (en) | Oral modified release formulations | |
US20240082268A1 (en) | Methods and compositions for controlling neuroinflammation | |
CN110418643A (zh) | 包含倍他司汀的鼻内组合物 | |
Patel et al. | Formulation considerations for improving intranasal delivery of CNS acting therapeutics | |
Tangri et al. | Nasal Drug Delivery Systems: Scope And Potential. | |
WO2014113564A1 (en) | New itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists | |
Katual et al. | Recent advancements in ropinirole hydrochloride embedded nano-techniques in Parkinson’s treatment | |
Afouna et al. | Influence of the Interplay between Azone™ as Permeation Enhancer a and Carbopol-974® as a Mucoadhesive upon the in vitro Transcorneal Release and the in vivo Antiglaucoma Effect of S-Timolol Maleate Ophthalmic Gel Formulations | |
JP2000072662A (ja) | 低血圧治療・予防用の貼付剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1137658 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1137658 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 |